JPRN-UMIN000003036已完成2 期
A phase ll study of adjuvant chemotherapy with Irinotecan (CPT-11) plus Nedaplatin (NDP) for stage lb2 or lla node-positive cervical cancer - A phase ll study of adjuvant chemotherapy for node-positive cervical cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients with paraaortic lymph node metastasis 2)Patients with positive histological margin 3)Patients with adnexal involvement 4)Patients with tumor extension to other organs 5) Patients with active infections 6) Patients with serious complications 7) Patients with active concomitant malignancy 8) Patients with interstitial pneumonia or pulmonary fibrosis 9) Patients with massive pleural, cardiac effusion, and/or ascites 10) Patients with coneraindication to CPT-11or NDP 11) Patients with diarrhea (watery stool) 12) Patients with intestinal paralysis or illeus 13) Patients with any history of serious drug reactions or hypersensitivity 14) Patients with HBs antigen 15)Patients who are inappropriate to enter this study with any safety reasons, judged by the treating physician
研究者
相似试验
已完成
1 期
Phase I study of combination chemotherapy with irinotecan hydrochroride(CPT-11) and nedaplatin(NDP) for locally advanced stage Ib2-IVa cervical cancer after Concurrent chemoradiotherapy (CCRT)Stage Ib2-IVa cervical cancerJPRN-UMIN000007458Japanese Gynecologic Oncology Group48
进行中（未招募）
不适用
Phase II study of Neo-adjuvant chemotherapy with letrozole in patients with estrogen receptor positive/HER-2 negative breast cancerKCT0008323ational Cancer Center114
已完成
2 期
A phase II study of first line chemotherapy by eribulin mesilate for HER2 negative recurrent breast cancerBreast cancerJPRN-UMIN000007990Kobe Breast Cancer Oncology Group35
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000008085Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)60
已完成
2 期
A Phase II study of Neoadjuvant chemotherapy in Tri-weekly nab-Paclitaxel followed by FEC with Operable HER2 Negative breast cancerHER2 negative operable breast cancerJPRN-UMIN000012909Kinki Breast Cancer Study Group-Translational Research (KBCSG-TR)120